慢性乙型肝炎病毒感染住院患者乙型肝炎e抗原和乙型肝炎病

StephenW

慢性乙型肝炎病毒感染住院患者乙型肝炎e抗原和乙型肝炎病毒抗体双重阳性的患病率刘媛媛1 2、松梅河2、司春银2、青阳钟2、钟建波2、张晓勇1、范荣1、侯锦林1 3隶属关系隶属关系    1    广东省广州市南方医科大学南方医院感染病科，器官衰竭研究国家重点实验室，广东省病毒性肝炎研究重点实验室。    2    广东省东莞市东莞市人民医院感染科。    3    南方医科大学深圳医院肝病科，广东省深圳市。    PMID：34557028 PMCID：PMC8454426 DOI：10.2147/IJGM.S328714抽象的目的：乙型肝炎病毒 (HBV) 患者通常不进行乙型肝炎 e 抗原 (HBeAg) 和乙型肝炎 e 抗体 (anti-HBe) 双阳性检测。本横断面研究旨在确定慢性乙型肝炎病毒感染 (C-HBVI) 住院患者中 HBeAg 和抗 HBe (DEP) 双阳性的患病率。患者和方法：回顾性分析了来自中国两个中心的 2820 例 C-HBVI 病例的数据。进行单变量和多变量逻辑回归分析以确定肝纤维化 (LF) 和急性加慢性肝衰竭 (ACLF) 的危险因素。结果：DEP、HBeAg+/抗-HBe-和HBeAg-/抗-HBe+组分别有165（5.9%）、688和1903名患者。 DEP 患者的中位年龄为 43.6 岁，其中 71.5% 为男性。他们的丙氨酸转氨酶、总胆红素和国际标准化比率水平较高。此外，DEP 病例的肝硬化比例更高，并且与 LF 的非侵入性检测相关，包括天冬氨酸转氨酶 (AST) 与血小板比率指数 (APRI) > 1.5（优势比 (OR) = 1.96， 95% 置信区间 (CI)：1.27-3.03，P = 0.002）和纤维化 4 (FIB-4) 得分 >1.45（OR = 2.07，95% CI：1.28-3.34，P = 0.003）。 DEP 也导致 ACLF 风险升高（OR = 4.80，95% CI：2.02-11.39，P < 0.001）。结论：与其他HBV感染患者相比，DEP病例发生LF和ACLF的风险更高。对 DEP 患者的肝脏疾病进行快速诊断和主动监测至关重要。关键词：乙肝e抗体；乙型肝炎e抗原。© 2021 刘等人。

StephenW

Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection
Yuanyuan Liu  1   2 , Songmei He  2 , Sichun Yin  2 , Qingyang Zhong  2 , Jianbo Zhong  2 , Xiaoyong Zhang  1 , Rong Fan  1 , Jinlin Hou  1   3
Affiliations
Affiliations

    1
    Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
    2
    Department of Infectious Diseases, Dongguan People's Hospital, Dongguan, Guangdong, People's Republic of China.
    3
    Hepatology Unit, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, People's Republic of China.

    PMID: 34557028 PMCID: PMC8454426 DOI: 10.2147/IJGM.S328714

Abstract

Objective: The detection of dual-positivity for both hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe) is not typically performed for patients with hepatitis B virus (HBV). This cross-sectional study was designed to figure out the prevalence of dual-positivity for both HBeAg and anti-HBe (DEP) among hospitalized patients with chronic hepatitis B virus infection (C-HBVI).

Patients and methods: Data from 2820 cases with C-HBVI from two centers in China were retrospectively analyzed. Univariate and multivariate logistic regression analyses were undertaken to identify the risk factors for liver fibrosis (LF) and acute-on-chronic liver failure (ACLF).

Results: There were 165 (5.9%), 688, and 1903 patients in DEP, HBeAg+/anti-HBe-, and HBeAg-/anti-HBe+ groups, respectively. The DEP patients' median age was 43.6 years old and 71.5% of them were male. They had higher levels of alanine transaminase, total bilirubin, and international normalized ratio. Furthermore, DEP cases had a higher proportion of liver cirrhosis, and it was associated with non-invasive testing of LF, including aspartate transaminase (AST)-to-platelet ratio index (APRI) >1.5 (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.27-3.03, P = 0.002) and fibrosis-4 (FIB-4) score >1.45 (OR = 2.07, 95% CI: 1.28-3.34, P = 0.003). DEP also contributed to the elevated risk of ACLF (OR = 4.80, 95% CI: 2.02-11.39, P < 0.001).

Conclusion: DEP cases are at higher risks of LF and ACLF than other patients with HBV infection. A fast diagnosis and an active monitoring of liver diseases for DEP patients are extremely vital.

Keywords: hepatitis B e antibody; hepatitis B e antigen.

© 2021 Liu et al.

StephenW

https://www.dovepress.com/getfile.php?fileID=73722